Patents Assigned to Aspen Park Pharmaceuticals
-
Patent number: 10758500Abstract: This invention provides: 1) a method of treating androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 2) a method of preventing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 3) a method of suppressing or inhibiting androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; and 4) a method of reducing the risk of developing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer, by administering to the subject a pharmaceutical composition comprising cis-clomiphene or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 24, 2019Date of Patent: September 1, 2020Assignee: ASPEN PARK PHARMACEUTICALS, INC.Inventors: Mitchell Steiner, Harry Fisch
-
Publication number: 20200085768Abstract: This invention provides: 1) a method of treating androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 2) a method of preventing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 3) a method of suppressing or inhibiting androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/ or hot flashes in a male subject suffering from prostate cancer; and 4) a method of reducing the risk of developing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/ or hot flashes in a male subject suffering from prostate cancer, by administering to the subject a pharmaceutical composition comprising cis-clomiphene or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 24, 2019Publication date: March 19, 2020Applicant: ASPEN PARK PHARMACEUTICALS , INC.Inventors: MITCHELL STEINER, HARRY FISCH
-
Patent number: 10463635Abstract: This invention provides: 1) a method of treating androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 2) a method of preventing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 3) a method of suppressing or inhibiting androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; and 4) a method of reducing the risk of developing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer, by administering to the subject a pharmaceutical composition comprising cis-clomiphene or a pharmaceutically acceptable salt thereof.Type: GrantFiled: January 25, 2018Date of Patent: November 5, 2019Assignee: ASPEN PARK PHARMACEUTICALS, INC.Inventors: Mitchell Steiner, Harry Fisch
-
Publication number: 20190133977Abstract: The present invention relates in certain embodiments to a controlled release formulation, especially a sachet, comprising a unit dosage of a dry powder of tamsulosin or a pharmaceutically acceptable salt thereof in a controlled release matrix and to methods of making and using such formulation. The controlled release formulation is beneficial in the treatment of benign prostatic hyperplasia (BPH), particularly in those patients suffering from dysphagia. The controlled release formulation is easily dispersed in water or other suitable liquid, and so solves the problem of dysphagia, thereby improving patient compliance in that targeted patient population, yet the controlled release formulation has a release profile in a patient on an empty stomach similar to FLOMAX® ((R)-5-(2-{[2-(2-Ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzene-1-sulfonamide hydrochloride) taken 30 minutes after a meal, but does not exhibit the FLOMAX® tablet food effect, thereby improving dosage form administration flexibility.Type: ApplicationFiled: May 4, 2017Publication date: May 9, 2019Applicant: ASPEN PARK PHARMACEUTICALS, INC.Inventors: K. Gary Barnette, Ruth E. Stevens, Kenneth V. Phelps, Lynn Gold
-
Publication number: 20190054044Abstract: The present invention relates to a pharmaceutical oral dosage form comprising both (A) trans-clomiphene or a pharmaceutically acceptable salt thereof and (B) cis-clomiphene or a pharmaceutically acceptable salt thereof, wherein (i) the ratio of (A):(B) in the dosage form is about 70:30; (ii) the amount of (A) in the dosage form is about 12.5 mg or about 25 mg; and (iii) the amount of (B) in the dosage form is less than 15 mg. The pharmaceutical oral dosage form is useful to treat secondary hypogonadism in men and minimize certain antiestrogenic drug side effects such as impaired cognition, hot flashes and bone loss, osteoporosis, and skeletal fractures.Type: ApplicationFiled: February 23, 2017Publication date: February 21, 2019Applicant: ASPEN PARK PHARMACEUTICALS, INC.Inventors: Mitchell Steiner, Harry Fisch
-
Publication number: 20190046465Abstract: The present invention relates to a sealed package containing one wipe, wherein the one wipe comprises a carrier and an active ingredient impregnated therein, wherein the active ingredient is selected from the group consisting of penile desensitizing agents. The sealed package can be opened, the wipe removed and wiped on the penis of a male to reduce the occurrence of premature ejaculation during subsequent intercourse. Repeated use of the wipes over time can result in statistically significant improvement in intravaginal ejaculatory latency time (IELT).Type: ApplicationFiled: May 10, 2018Publication date: February 14, 2019Applicant: ASPEN PARK PHARMACEUTICALS, INC.Inventor: HARRY FISCH
-
Publication number: 20180153829Abstract: This invention provides: 1) a method of treating androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 2) a method of preventing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 3) a method of suppressing or inhibiting androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; and 4) a method of reducing the risk of developing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer, by administering to the subject a pharmaceutical composition comprising cis-clomiphene or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: January 25, 2018Publication date: June 7, 2018Applicant: ASPEN PARK PHARMACEUTICALS, INC.Inventors: MITCHELL STEINER, Harry Fisch
-
Patent number: 9913815Abstract: This invention provides: 1) a method of treating androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 2) a method of preventing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 3) a method of suppressing or inhibiting androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; and 4) a method of reducing the risk of developing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer, by administering to the subject a pharmaceutical composition comprising cis-clomiphene or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 23, 2015Date of Patent: March 13, 2018Assignee: ASPEN PARK PHARMACEUTICALS, INC.Inventors: Mitchell Steiner, Harry Fisch
-
Publication number: 20170202788Abstract: This invention provides: 1) a method of treating androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 2) a method of preventing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 3) a method of suppressing or inhibiting androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; and 4) a method of reducing the risk of developing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer, by administering to the subject a pharmaceutical composition comprising cis-clomiphene or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 23, 2015Publication date: July 20, 2017Applicant: ASPEN PARK PHARMACEUTICALS , INC.Inventors: MITCHELL STEINER, HARRY FISCH
-
Publication number: 20160346223Abstract: The present invention relates to a sealed package containing one wipe, wherein the one wipe comprises a carrier and an active ingredient impregnated therein, wherein the active ingredient is selected from the group consisting of penile desensitizing agents. The sealed package can be opened, the wipe removed and wiped on the penis of a male to reduce the occurrence of premature ejaculation during subsequent intercourse.Type: ApplicationFiled: January 20, 2015Publication date: December 1, 2016Applicant: Aspen Park PharmaceuticalsInventor: HARRY FISCH